tradingkey.logo

Roxadustat Granted Orphan Drug Designation For The Treatment Of Myelodysplastic Syndromes By The U.S. FDA

ReutersDec 15, 2025 12:11 PM

- FibroGen Inc FGEN.O:

  • ROXADUSTAT GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES BY THE U.S. FOOD AND DRUG ADMINISTRATION

  • FIBROGEN INC - TO FILE PHASE 3 PROTOCOL IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI